BioPharmSignal logoBioPharmSignal

Biotech News

Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update

Rhythm Pharmaceuticals (RYTM)Rhythm PharmaceuticalsEarnings

-- Strong U.S. launch momentum for IMCIVREE ® (setmelanotide) for acquired hypothalamic obesity (HO) continues with more than 700 patient start forms as of September 30, 2026 --

-- Third quarter 2026 net product revenue from global sales of IMCIVREE of $92.1 million, an increase of 29% from the prior quarter --

-- Commercial launch of IMCIVREE in Japan for patients with acquired HO underway --

-- Bivamelagon to advance into pivotal development in Prader-Willi syndrome --

Related news

RYTMRhythm Pharmaceuticals2026-10-21 12:00 EST

Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026

RYTMRhythm Pharmaceuticals2026-08-04 11:01 EST

Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

MISTMilestone Pharmaceuticals Inc.2026-11-03 13:00 EST

Milestone Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 13, 2026

LXRXLexicon Pharmaceuticals2026-10-29 12:30 EST

Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026

MISTMilestone Pharmaceuticals Inc.2026-08-12 11:08 EST

Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update

LXRXLexicon Pharmaceuticals2026-08-06 11:30 EST

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

ALGSAligos Therapeutics2026-11-06 13:00 EST

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results

CVRXCVRx2026-11-05 21:05 EST

CVRx Reports Third Quarter 2026 Financial and Operating Results

MNKDMannKind2026-11-05 21:01 EST

MannKind Reports Third Quarter 2026 Financial Results and Provides Business Update

MLYSMineralys Therapeutics2026-11-04 21:05 EST

Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

View all latest news

Rhythm Pharmaceuticals

Rare Neuroendocrine Diseases Rhythm Pharmaceuticals develops and commercializes therapies for rare neuroendocrine disorders characterized by pathological hunger and severe obesity. Its programs focus on restoring melanocortin-4 receptor pathway signaling in genetically or structurally defined patient populations. IMCIVREE...

Recent company news

RYTMRhythm Pharmaceuticals2026-11-04 13:00 EST

Rhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE® (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl Syndrome

RYTMRhythm Pharmaceuticals2026-11-03 12:00 EST

Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update

RYTMRhythm Pharmaceuticals2026-11-03 02:59 EST

Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement

RYTMRhythm Pharmaceuticals2026-10-21 12:00 EST

Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026

RYTMRhythm Pharmaceuticals2026-10-13 23:30 EST

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity

Stock data

Close
105.02 USD
Market cap
5.79B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States